These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 25943176)

  • 21. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
    David OJ; Ocwieja M; Meiser K; Emotte C; Jakab A; Wemer J; den Daas I; Schmouder R
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):540-4. PubMed ID: 22735460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
    Kuhnz W; al-Yacoub G; Fuhrmeister A
    Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics
.
    Adedoyin A; Cho CR; Fox-Bosetti S; Macha S; Zhao T; Liu F; Panebianco D; O'Reilly TE; McCrea J; Stoch SA; Iwamoto M
    Int J Clin Pharmacol Ther; 2019 Sep; 57(9):450-457. PubMed ID: 31232280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
    Kothare PA; Seger ME; Northrup J; Mace K; Mitchell MI; Linnebjerg H
    BMC Clin Pharmacol; 2012 Mar; 12():8. PubMed ID: 22429273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination.
    Heger-Mahn D; Pabst G; Dienel A; Schläfke S; Klipping C
    Drugs R D; 2014 Dec; 14(4):265-72. PubMed ID: 25319228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zibotentan Can Be Co-administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug-Drug Interaction Study.
    Mercier AK; Kois AK; Karsanji D; Baldry R; Birve F; Hedwall M; Molodetskyi O; Gillen M
    Clin Pharmacol Ther; 2024 Aug; 116(2):372-379. PubMed ID: 38686600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1, open-label study to evaluate the drug interaction between islatravir (MK-8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
    Ankrom W; Jackson Rudd D; Zhang S; Fillgrove KL; Gravesande KN; Matthews RP; Brimhall D; Stoch SA; Iwamoto MN
    J Int AIDS Soc; 2021 Dec; 24(12):e25858. PubMed ID: 34935295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
    Jacobsen LV; Vouis J; Hindsberger C; Zdravkovic M
    J Clin Pharmacol; 2011 Dec; 51(12):1696-703. PubMed ID: 21228406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
    Archer DF; Stanczyk FZ; Rubin A; Foegh M
    Contraception; 2013 Feb; 87(2):212-9. PubMed ID: 23158806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BMI, pharmacokinetics, and OCP failure.
    Cherala G; Edelman A
    Contraception; 2010 Dec; 82(6):582; author reply 581-2. PubMed ID: 21074028
    [No Abstract]   [Full Text] [Related]  

  • 31. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users.
    Edelman AB; Cherala G; Munar MY; Dubois B; McInnis M; Stanczyk FZ; Jensen JT
    Contraception; 2013 Feb; 87(2):220-6. PubMed ID: 23153898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women.
    Barcellos T; Natavio M; Stanczyk FZ; Luo D; Jusko WJ; Bender NM
    Contraception; 2019 Oct; 100(4):283-287. PubMed ID: 31194965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.
    Menon S; Riese R; Wang R; Alvey CW; Shi H; Petit W; Krishnaswami S
    Clin Pharmacol Drug Dev; 2016 Sep; 5(5):336-42. PubMed ID: 27138968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
    Marshall WL; Feng HP; Caro L; Talaty J; Guo Z; Huang X; Panebianco D; Ma J; Mangin E; O'Reilly TE; Butterton JR; Yeh WW
    Eur J Clin Pharmacol; 2017 May; 73(5):593-600. PubMed ID: 28233047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of Drug-Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers.
    Begley R; Anderson K; Watkins TR; Weng W; Ampaw L; Qin A; Kearney BP; Mathias A
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):376-383. PubMed ID: 32989920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
    Teichmann A; Apter D; Emerich J; Greven K; Klasa-Mazurkiewicz D; Melis GB; Spaczynski M; Grubb GS; Constantine GD; Spielmann D
    Contraception; 2009 Dec; 80(6):504-11. PubMed ID: 19913143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
    Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
    Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determining the Exposure Threshold for Levonorgestrel Efficacy Using an Integrated Model Based Meta-Analysis Approach.
    Lingineni K; Chaturvedula A; Cicali B; Cristofoletti R; Wendl T; Hoechel J; Brown JD; Vozmediano V; Schmidt S
    Clin Pharmacol Ther; 2022 Feb; 111(2):509-518. PubMed ID: 34674227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
    Griffith SG; Dai Y
    Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women.
    Trezza C; Ford SL; Gould E; Lou Y; Huang C; Ritter JM; Buchanan AM; Spreen W; Patel P
    Br J Clin Pharmacol; 2017 Jul; 83(7):1499-1505. PubMed ID: 28087972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.